MIRA
NASDAQ · Pharmaceuticals
Mira Pharmaceuticals Inc
$0.99
-0.01 (-1.30%)
Financial Highlights (FY 2025)
Revenue
15.23M
Net Income
2.05M
Gross Margin
41.2%
Profit Margin
13.5%
Rev Growth
+3.2%
D/E Ratio
0.43
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 41.2% | 41.2% | 41.2% |
| Operating Margin | 21.6% | 21.7% | 21.1% |
| Profit Margin | 13.5% | 16.2% | 13.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.23M | 13.68M | 17.07M |
| Gross Profit | 6.28M | 5.64M | 7.04M |
| Operating Income | 3.29M | 2.97M | 3.60M |
| Net Income | 2.05M | 2.22M | 2.28M |
| Gross Margin | 41.2% | 41.2% | 41.2% |
| Operating Margin | 21.6% | 21.7% | 21.1% |
| Profit Margin | 13.5% | 16.2% | 13.3% |
| Rev Growth | +3.2% | +10.2% | +2.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 11.14M | 9.95M | 10.29M |
| Total Equity | 25.74M | 26.89M | 28.51M |
| D/E Ratio | 0.43 | 0.37 | 0.36 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.17M | 3.79M | 4.72M |
| Free Cash Flow | 3.12M | 1.71M | 2.33M |